Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment ...

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial ...

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, ...

--Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and ...

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma Nov. 10, 2022 9:00 AM ET Ikena Oncology, Inc. (IKNA) Q3: 2022-11-07 Earnings Summary ...

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Ikena Oncology, Inc. Thu, Nov 9, 2023, 7: ...

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial ...

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria . Tuesday, 02 January 2024 12:17 GMT.

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial ...

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial ...

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial ...